- Home
- AQMS vs BCDA Comparison
AQMS vs BCDA Comparison
Compare AQMS & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQMS
- BCDA
- Stock Information
- Founded
- AQMS 2014
- BCDA N/A
- Country
- AQMS United States
- BCDA United States
- Employees
- AQMS N/A
- BCDA N/A
- Industry
- AQMS Metal Fabrications
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- AQMS Industrials
- BCDA Health Care
- Exchange
- AQMS Nasdaq
- BCDA Nasdaq
- Market Cap
- AQMS 11.1M
- BCDA 9.4M
- IPO Year
- AQMS 2015
- BCDA N/A
- Fundamental
- Price
- AQMS $1.15
- BCDA $2.32
- Analyst Decision
- AQMS Strong Buy
- BCDA Strong Buy
- Analyst Count
- AQMS 3
- BCDA 1
- Target Price
- AQMS $21.00
- BCDA $25.00
- AVG Volume (30 Days)
- AQMS 161.4K
- BCDA 102.2K
- Earning Date
- AQMS 05-08-2025
- BCDA 05-14-2025
- Dividend Yield
- AQMS N/A
- BCDA N/A
- EPS Growth
- AQMS N/A
- BCDA N/A
- EPS
- AQMS N/A
- BCDA N/A
- Revenue
- AQMS N/A
- BCDA $58,000.00
- Revenue This Year
- AQMS N/A
- BCDA N/A
- Revenue Next Year
- AQMS $550.00
- BCDA N/A
- P/E Ratio
- AQMS N/A
- BCDA N/A
- Revenue Growth
- AQMS N/A
- BCDA N/A
- 52 Week Low
- AQMS $1.05
- BCDA $1.63
- 52 Week High
- AQMS $10.44
- BCDA $6.15
- Technical
- Relative Strength Index (RSI)
- AQMS 41.16
- BCDA 45.74
- Support Level
- AQMS $0.93
- BCDA $2.40
- Resistance Level
- AQMS $1.05
- BCDA $2.92
- Average True Range (ATR)
- AQMS 0.11
- BCDA 0.31
- MACD
- AQMS -0.00
- BCDA -0.00
- Stochastic Oscillator
- AQMS 43.43
- BCDA 9.28
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).